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1. Abstract 
 This project is an examination of the use of deep brain stimulation (DBS) in the 
treatment of Parkinson's disease. The project contains an overview of the areas of the 
brain that are affected by Parkinson's disease and that are targeted by deep brain 
stimulation for treatment. The function and anatomy of these regions are discussed. The 
history of deep brain stimulation is examined, as are new methods and theories as to 
how deep brain stimulation can be used more effectively to treat not only Parkinson's 
disease, but other diseases as well. Case studies are presented and examined. We 
conclude that deep brain stimulation  remains a valuable tool for treating Parkinson's 
disease, recommend that deep brain stimulation be used more aggressively as a 
treatment in the early stages of Parkinson’s disease, and call for deep brain stimulation 
to be used as a treatment for a wider variety of illnesses. 
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2. Abbreviations 
 ATP - adenosine triphosphate  
 COMT - catechol-O-methyl transferase  
 CT - computed tomography  
 cZI - caudal zona incerta  
 DA - dopamine  
 DBS - deep brain stimulation  
 GP - globus pallidus  
 GPi - internal globus pallidus  
 HVA - homovanilic acid  
 ICD - impulse control disorder  
 IPG - internal pulse generator  
 iPSC - induced pluripotent stem cell  
 MAO - monoamine oxidase  
 MAOI - monoamine oxidase inhibitor  
 MDD - major depressive disorder  
 MRI - magnetic resonance imaging  
 NO - nitric oxide  
 OCD - obsessive-compulsive disorder  
 PD - Parkinson's disease  
 PET - positron emission tomography  
 PPN - pedunculopontine nucleus  
 SN - substantia nigra  
 SNpc - substantia nigra pars compacta  
 TH - tyrosine hydroxylase  
 UPDRS - Unified Parkinson's Disease Rating Scale 
 USFDA - United States Food and Drug Administration  
 Vim - ventralis intermedius thalamus 
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3. Problem formulation 
With this project, we want to ask “how does deep brain stimulation work in the 
treatment of Parkinson's disease, how effective is deep brain stimulation in treating 
Parkinson's disease, and how can deep brain stimulation be more effective?” We plan to 
answer these questions by studying published, clinical investigations of the use of deep 
brain stimulation in Parkinson’s disease patients as well as primary research articles on 
the molecular and physiological mechanisms by which deep brain stimulation works. 
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4. Introduction 
 Parkinson's disease is a neurological condition that results from the death of 
dopamine-producing neurons in the substantia nigra pars compacta (SNpc), a structure 
in the basal ganglia. Those with Parkinson’s disease suffer from a variety of movement 
related disorders, such as tremors, difficulty maintaining posture, and bradykinesia 
(slow, labored movement). Parkinson’s disease is a degenerative disease; over time, cell 
death in the SNpc becomes worse and worse, as do the resultant symptoms [Wichmann 
et al, 2011]. It is a disease that typically affects older adults. There currently exists no 
cure for Parkinson’s disease and, because of increased average longevity, Parkinson’s 
disease is a disease that can be expected to appear with more frequency. 
 Parkinson’s disease is often treated with L-dopa, a precursor chemical to 
dopamine that stimulates dopamine production in the SNpc. Over time, however, the 
SNpc becomes so thoroughly destroyed that L-dopa ceases to work as a treatment. 
Another treatment is deep brain stimulation (DBS), where electrodes are implanted in 
the brain to stimulate the basal ganglia [Hickey & Stacy, 2011]. The areas to which deep 
brain stimulation are most frequently applied are the internal globus pallidus, the 
subthalamic nucleus and the ventral intermediate nucleus. The exact mechanism by 
which deep brain stimulation works is not understood, but the areas that are stimulated 
are those that are acted upon by the SNpc under normal conditions [Shah et al, 2010]. 
It is estimated that there are between 7 and 10 million people living with 
Parkinson’s worldwide [PDF, 2012]. So far there are around 60.000 Parkinson’s patients 
who have undergone deep brain stimulation surgery worldwide. It is expected that there 
will be 8.000-10.000 new Parkinson’s patients who will undergo DBS surgery every 
year worldwide. [Ponce & Lozano, 2010]. 
 Deep brain stimulation has existed since the 19th century and has seen more 
routine use in recent decades as a treatment for many neurological conditions, among 
them Parkinson’s disease. Advances in neuroimaging technology coupled with a greater 
understanding of the anatomy of the brain have led to experiments for how best to use 
deep brain stimulation. It is known, for example, that deep brain stimulation can work 
after the SNpc has been damaged to the point that L-dopa treatment is no longer 
effective, but experiments now show that deep brain stimulation can be applied earlier, 
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while L-dopa treatment is still effective, in order to increase the effectiveness of L-dopa. 
deep brain stimulation may therefore be effective as a treatment for more patients than it 
is currently used for [Hickey & Stacy, 2011]. Who is helped the most, how, and why are 
all questions that remain to be answered. 
 Deep brain stimulation is not without drawbacks. While it can very effectively 
and dramatically address the tremors and movement difficulties associated with 
Parkinson’s disease, deep brain stimulation has been known to produce side-effects 
ranging from worsened movement symptoms to compulsive gambling. The 
dopaminergic system is delicate, but powerful and changes to it can result in dramatic 
changes in behaviour. Deep brain stimulation has been proven to work to treat 
Parkinson’s disease and is a technology that has the potential to be used more 
effectively in the future. However, in order to develop it further it is necessary to study 
deep brain stimulation and to better understand the precise effects that deep brain 
stimulation has on the brain areas it targets, on the brain's dopamine pathways. 
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5. The Motor System 
 From an evolutionary perspective, the ability to move is one of the oldest 
abilities that vertebrates share. Many elements in the central nervous system work 
together to allow organisms to move their bodies in a useful, coherent fashion. From 
nerves in the spinal cord that control involuntary reflexes to complex, coordinated 
movements that are planned in the higher brain areas, much of the brain consists of 
neurons that ensure that the organism can move and function in its environment. 
 Some of the older structures involved in movement are the basal ganglia. In 
humans, the basal ganglia are part of the midbrain, above the brain stem but buried 
under the more evolutionarily recent cortices. The basal ganglia are a collection of 
several structures – nuclei – that includes the globus pallidus, the putamen, and the 
caudate nucleus. The latter two are also known collectively as the striatum. The nuclei 
of the basal ganglia are connected to many other parts of the brain that also handle 
movement, including the thalamus and the motor cortices, both of which are superior to 
(ie above, towards the top of the skull when standing) the basal ganglia [Rosenzweig et 
al, 2005]. Inputs to the basal ganglia from the motor cortex are received by the striatum. 
The striatum passes along signals to the subthalamic nucleus and globus pallidus. 
Excitatory pathways from the motor cortices extend directly to the subthalamic nucleus, 
providing it with another source of input [Levy et al, 2002]. Signals passed to the 
subthalamic nucleus are carried on to the substantia nigra [Lozano & Mahant, 2004]. 
 
Figure 5.1. Illustrates the basal ganglia 
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5.1. The nigrostriatal pathway 
The nuclei of the basal ganglia and, in particular, the striatum are stimulated by 
dopamine that they receive from a nearby structure, the substantia nigra pars compacta 
(SNpc) [Delong & Wichmann, 2010]. The flow of dopamine from the substantia nigra 
to the striatum and the globus pallidus constitutes the first step of the nigrostriatal 
pathway. The nigrostriatal pathway plays an important role in the motor system. The 
steady flow of dopamine from the substantia nigra pars compacta through the pathway 
is necessary for a healthy, functioning basal ganglia, which is in turn necessary for 
modulating movement. 
 
Figure 5.1.1. Diagram illustrating the connections of the structures of the nigrostriatal pathway. 
 In looking at the effects of the nigrostriatal pathway, it is illustrative to look at 
Parkinson's disease. Parkinson's disease occurs due to a break-down of the nigrostriatal 
pathway. The motor symptoms of Parkinson's disease (described in detail in section 6) 
all arise from an insufficient supply of dopamine to the structures of the basal ganglia. 
Under normal circumstances, the striatum and other basal ganglia structures are 
constantly supplied with a steady stream of dopamine, regardless of whether the body is 
in motion or at rest [Bergquist & Nissbrandt, 2005]. 
 The neurotransmitters glutamate, which is excitatory, and GABA, which is 
inhibitory, are regulators of dopamine release for the substantia nigra pars compacta 
[Sherman, 2005]. Dopamine release in the striatum is heavily regulated by GABA and 
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glutamate. Dopamine release in the substantia nigra pars compacta can be increased by 
stimulating cells that produce/release glutamate [Bergquist & Nissbrandt, 2005], such as 
those of the subthalamic nucleus [Chatha et al, 2000]. In the striatum, nitric oxide (NO) 
produced endogenously from arginine, NADPH and O2 also stimulates dopamine 
release [Harsing, 2008]. 
5.2. Inter-neuron signalling in the basal ganglia 
 To understand how signals pass from one structure of the brain to another it is 
necessary to know how neurons function, and so a brief review of long-distance 
communication between neurons will now be presented. Neurons are the cells in brain 
tissue that work together to perform the various functions that occur in the brain. The 
typical neuron has a star-shaped body, the soma, with many branch-like projections, the  
dendrites. Most neurons also have an  extension coming from the soma, called an axon. 
The axon is partially sheathed in a substance called myelin, with small, exposed gaps. 
At the end of the axon are the axon terminals. Human sensory and motor nerves may 
have axons up to 1 m long. 
 Neurons communicate with chemical signals, neurotransmitters, over a small 
gap between the two neurons called a synapse. The neuron that releases 
neurotransmitters - that is, the neuron that is sending the signal - is the pre-synaptic 
neuron. The neuron that receives the "message" is the post-synaptic neuron. The 
synapse lies between the axon terminals of the pre-synaptic neuron and the dendrites of 
the post-synaptic neuron, however, dendrite-to-dendrite signalling also takes place. 
When signal transduction takes place between neurons, the dendrite or axon terminals 
of the pre-synaptic neuron release neurotransmitters into the synaptic cleft. These 
neurotransmitters then act as ligands and bind to receptors on the membrane of the post-
synaptic neuron. 
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Figure 5.2.1. Illustrates how neurons communicate with chemical signals, neurotransmitters  
The dopaminergic neurons that make up the substantia nigra are large, have a 
large Golgi apparatus, and have dendrites with many receptors for the neurotransmitter 
GABA. Synthesis of dopamine and the packaging of dopamine into vesicles for release 
take place at the axon terminals, in the cytosol. Dopamine - also, adrenaline 
(epinephrine) and noradenaline (norepinephrine) - is synthesized by the enzymes 
tyrosine hydroxylase and Dopa decarboxylase. This process is explained in greater 
detail in section 5.4. The axons of the dopaminergic neurons of the substantia nigra pass 
through the globus pallidus en route to the striatum [McGeer et al, 1978]. 
 Neurons signal to one another, release neurotransmitters, in response to changes 
in their electrical charge. When a neuron is not being stimulated or inhibited, it will be 
at its resting membrane potential. This potential - difference in charge between the 
interior of the cell and the area just outside the plasma membrane - is between -70 and -
80 millivolts for neurons. Because the interior of the neuron has a negative charge 
relative to the exterior, the potential is expressed as a negative number. There is a higher 
concentration of sodium, Na+, ions outside of the neuron than in the cytosol; potassium, 
K+, ions are found in higher concentration in the cytosol than outside the cell 
[Gazzaniga et al, 2002]. These concentration differences are maintained via the ATP-
driven sodium-potassium pump. 
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Figure 5.2.2. Time v. membrane voltage before, during, and after an action potential 
 Changes in the charge within the neuron can result in a so-called action 
potential. An action potential occurs when sections of membrane on a neuron are rapidly 
depolarized (the charge goes from negative to positive). The plasma membrane of a 
neuron can be depolarized in multiple places simultaneously, if the neuron is receiving 
multiple inputs. When a region of the membrane is depolarized, voltage-gated ion 
channels in the plasma membrane open, allowing positively-charged sodium ions to 
enter the neuron. The sodium ions are driven by passive transport along their electrical 
and concentration gradients. As more sodium ions enter the neuron, the interior of the 
neuron becomes even more depolarized (ie the cytosolic electrical charge becomes less 
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negative/more positive). If the charge in the neuron reaches a certain threshold - around 
-55 millivolts - an action potential will occur. 
 Once an action potential has been triggered, voltage-gated ion channels that had 
been open, allowing in sodium ions, close. Potassium ions (K+) leave the neuron, 
driving down the overall charge within the neuron (repolarization). Sodium-potassium 
pumps in the plasma membrane exchange sodium ions in the cytosol for potassium ions 
in the extracellular fluid. This energy-requiring pumping is fuelled by ATP. The charge 
in the neuron returns to the resting state, with more K+ ions inside the neuron and more 
Na+ ions outside the plasma membrane, and repolarization is complete. If the threshold 
for activation is not reached while depolarisations are occurring, the neuron will use this 
process to return itself to resting potential. For an action potential to occur, the 
depolarization of the neuron must occur faster than the resting potential restoring 
process. 
When depolarization does occur rapidly enough to trigger an action potential, 
the action potential travels down the axon of the neuron to the axon terminals. Upon the 
arrival of the action potential, the axon terminals are depolarized. The depolarization of 
the axon terminals causes neurotransmitter-containing vesicles in the axon terminals to 
merge with the (pre-synaptic) neuron's plasma membrane (cell membrane), pushing the 
neurotransmitters out of the axon and into the synapse. The neurotransmitters diffuse 
throughout the synapse and bind to receptor proteins in the post-synaptic plasma 
membrane via weak interactions (ionic, van der waal, hydrogen bonds).  
There are two main classes of neurotransmitter receptors found on the post-
synaptic neuron, directly coupled and indirectly coupled receptors. Directly coupled 
post-synaptic receptors are ion channels that open when a neurotransmitter molecule 
binds with them. Indirectly coupled post-synaptic receptors involve G-proteins and 
second messengers. With indirectly coupled receptors, second messengers are released 
in the cytosol following the binding of neurotransmitter and receptor. Calcium ions, 
Ca2+, are a common second messenger in this process, as are c-GMP and c-AMP 
[Gazzaniga et al, 2002]. 
 Dopamine receptors are indirectly coupled receptors that use c-AMP as a second 
messenger. The many types of dopamine receptors are grouped into two large groups: 
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D1-like receptors, which are excitatory, and D2-like receptors, which are inhibitory. The 
neurons of the striatum, which receives the majority of the outputs from the substantia 
nigra pars compacta, contains both D1-like and D2-like receptors [Bracci et al, 2002]. 
 The receptor proteins of the post-synaptic neuron are eventually "switched off", 
when the ligand leaves the receptor, either by diffusion or due to enzymatic breakdown. 
between receptor and ligand (neurotransmitter). The neurotransmitters remain in the 
synapse until they are either taken up again by the pre-synaptic neuron, are broken 
down by enzymes, or until the neurotransmitters diffuse away from the synapse. 
Catecholamines, including dopamine, may be taken up again by the pre-synaptic neuron 
and/or degraded into simpler molecules by enzymes. The reuptake process uses active 
transport, with transmembrane protein pumps. Enzymatic breakdown occurs when 
either monoamine oxidase (MAO) or catechol-O-methyl transferase (COMT) is 
released into the synapse [Gazzaniga et al, 2002]. This process is described in greater 
detail in section 5.5.1.  
 Direct stimulation of the nuclei of the basal ganglia does not result in movement, 
yet healthy basal ganglia are critical for the organism to move fluently. The basal 
ganglia work to modulate and regulate an organism's movement rather than to direct and 
control the movements. The basal ganglia's modulations are inhibitory. Another brain 
structure, the cerebellum, performs the same function, but in the opposite direction; the 
modulations on movement that come from the cerebellum are excitatory [Widmeier et 
al, 2008]. An organism with a damaged cerebellum will have difficulties beginning 
movements, while an organism with damaged basal ganglia will experience jerking, 
out-of-control movements [McGeer et al, 1978]. In order to be able to execute fluid 
movements, an organism must have both healthy basal ganglia and a healthy cerebellum 
so that the two structures may work together harmoniously. 
5.3. Excitotoxicity 
Glutamate is not only the most abundant excitatory neurotransmitter in the 
central nervous system, but it is also - potentially - a neurotoxin. High concentrations of 
glutamate can lead to excitotoxicity, a condition wherein neurons become damaged and 
die following excessive excitation. When glutamate binds to receptors on a (post-
synaptic) neuron, ion-channels open which allow in extracellular calcium ions, Ca2+. 
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This is beneficial in rapidly depolarizing the neuron, but is harmful in excess. When too 
many calcium ions flood the cytosol, serious harm can occur. The mitochondria are 
damaged, causing them to stop ATP production, and cascading chemical reactions cause 
damage to components of the cell, including DNA, culminating in cell death [Farooqui 
et al, 2008]. 
Excitotoxicity leading to damage and death of neurons is of particular interest in 
treating and preventing Parkinson's disease. The substantia nigra pars compacta receives 
many excitatory glutamate inputs, for example from the subthalamic nucleus. 
Overstimulation of the SNpc by these routes could explain the degradation of the 
dopaminergic SNpc neurons. Treatment of Parkinson's disease by modulating the 
glutamate pathway between the subthalamic nucleus and the substantia nigra is 
discussed in section 6.2.2. 
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5.4. Dopamine synthesis 
 The synthesis takes place in the cytoplasm of the nerve cell. Eventually 
dopamine is formed out of tyrosine. Tyrosine is one of the non-essential amino acids 
produced in our body. Non-essential amino acids are amino acids we do not necessarily 
need to obtain from our food; we can synthesize them in our bodies.  
 
 
Figure 5.4.1. Synthesis of the catecholamine neurotransmitters  
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The difference between L-dopa and tyrosine is that L-dopa has an additional 
alcohol group compared to tyrosine.  
Once tyrosine has been converted to L-dopa, L-dopa needs to be converted to dopamine 
for our purposes. To do this, the enzyme Dopa decarboxylase is needed.  
L-Dopa turns into dopamine as a carboxylic acid group is removed. Dopa decarboxylase 
requires a cofactor, pyridoxal phosphate, in order to perform the reaction. As can be 
seen on figure 5.4.1. the waste product of this reaction is CO2. 
 From there, dopamine can be further oxidized. When this happens, it becomes 
norepinephrine. Finally, noradrenaline can be methylated using S-adenosylmethionine, 
creating epinephrine.  Both norepinephrine and epinephrine are different 
neurotransmitters. All three neurotransmitters that are formed from the amino acid 
tyrosine are called monoamines, because they consist of one carbon ring and one amino 
group. More specifically these three neurotransmitters are also called catecholamines 
because they consist of a catechol group and an amino group.  
 5.5. Decomposition of monoamines 
One of the ways that monoamines are decomposed is by enzymatic breakdown. 
The enzymes responsible for this breakdown are called monoamine oxidases (MAOs). 
These monoamine oxidases are commonly divided into two, MAO A and MAO B, 
though the mechanisms used by these enzymes are still discussed [Erdem & 
Büyükmenekşe, 2011]. 
5.5.1. Decomposition of dopamine 
 Dopamine is oxidized by monoamine oxidase to 3,4-
dihydroxyphenylacetaldehyde , which is oxidized to 3,4-dihydroxyphenylacetic acid by 
aldehyde dehydrogenase. This metabolite is then methylated by catechol-O-methyl 
transferase (COMT) to homovanilic acid (HVA).  
COMT can also methylate dopamine to 3-methoxytyramine which is oxidized to HVA 
by MAO. HVA is then excreted in the urine (figure 5.5.1.). 
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Figure 5.5.1. Decomposition of dopamine 
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6. Parkinson’s disease 
Parkinson’s disease is mostly seen in elderly people over fifty years old who 
have experienced cell death in the basal ganglia. The cause of the cell death that 
characterizes Parkinson's disease is not necessarily always clear and most of the cases 
are classified as idiopathic.  
 Parkinson’s disease is known for symptoms regarding movement. It can cause 
tremors, uncontrolled shaking, bradykinesia (slow, labored movement), akinesia (lack of 
movement), and other complications involved with movement. The symptoms of 
Parkinson’s disease are caused by death of cells in the substantia nigra pars compacta 
(SNpc), one of the basal nuclei. The substantia nigra pars compacta synthesizes the 
neurotransmitter dopamine (DA) and releases it to nearby basal ganglia. When the 
dopamine supply from the SNpc to these areas is reduced or eliminated completely, the 
motor control problems that are characteristic to Parkinson’s disease emerge (tremors, 
bradykinesia, dystonia, etc.) [Shah et al, 2010].  
 
Figure 6.1.1. Illustrates the difference in the substantia nigra between a healthy person and a person with 
Parkinson’s disease. 
Besides the motor dysfunctions, neuropsychiatric complications in Parkinson’s 
disease are nowadays also commonly recognised. Several disorders have been 
diagnosed with significant frequency, including depression, psychosis and impulse 
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control disorders. The specific effects of the neuropsychiatric disorder are unique to 
each patient [Weintraub & Burn, 2011]. 
 Depression is one of the disorders that is fairly often accompanied by 
Parkinson’s disease with numbers varying from 5% to 20%. Up to 25% of all the 
Parkinson’s disease patients have been treated with antidepressants at some time, 
antidepressants does not only work against depression but also other diseases 
[Weintraub & Burn, 2011].  
 Impulse control disorders (ICDs) are another type of disorder that is related to 
Parkinson’s disease. ICDs include, for example, compulsive gambling, eating or buying. 
In nearly 14% of the Parkinson’s disease patients ICDs were identified [Weintraub et al, 
2010]. A patient using dopamine agonist was more likely to suffer from ICDs. 
6.1. Lewy bodies 
Patients with Parkinson’s disease are often characterised by  Lewy bodies which 
can be found  in nerve cells in the brain. Lewy bodies consist primarily of α-synuclein, a 
protein that may be linked to dopamine release, along with other proteins of its kind.  In 
α-synuclein knockout mice, mice genetically engineered not to produce α-synuclein, 
increased release of dopamine was observed. This observation could mean that α-
synuclein is a negative regulator of dopamine [Tofaris & Spillantini, 2005].  
Polymeropoulos et al found that there was a point mutation in the gene coding 
for α-synuclein in a group of families [Polymeropoulos et al, 1997]. This group of 
families had autosomal dominant inheritance of the Parkinson’s disease phenotype. This 
also suggests the relationship of Lewy bodies and Parkinson’s disease. The point 
mutation that the researchers found was located on the fourth exon of the α-synuclein 
gene. This resulted in the insertion of threoninen instead of alanine in position 53 in the 
protein. 
6.2. Treatments for Parkinson's disease 
Treatments for Parkinson's disease have focused primarily on the motor 
problems that are the classic symptoms of the disease. There exist many treatments that 
are effective to different degrees and that have a range of different side-effects. Some 
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treatments are used in conjunction with one another to maximize the effectiveness of 
each. 
In Parkinson's disease, the relation between the motor function and the non-
motor function is complex. To find a good treatment for Parkinson’s disease is therefore 
also rather complicated. 
There are a few different treatments available to lower the severity of the Parkinson’s 
disease symptoms. 
6.2.1. Ablation/Lesioning 
Surgical destruction of nuclei in the basal ganglia, also known as "ablation" or 
"lesioning", is a well-known method for treating some parkinsonian symptoms. Tremor 
and rigidity can both be effectively treated by ablation of the ventrolateral nuclei of the 
thalamus. This treatment does not, however, lead to improvements across the board: 
bradykinesia and akinesia are unaffected. Ablation fell out of favor as a treatment for 
Parkinson's disease with the discovery of medicinal L-Dopa treatment, which has the 
advantages of being non-invasive and of treating not only tremor and rigidity, but also 
akinesia, bradykinesia [McGeer et al, 1978]. Ablation remains a common practice in 
regions of the world where deep-brain stimulation is not available due to lack of 
expertise [Wichmann & Delong, 2011]. Because ablation involves destroying brain 
tissue, it is obviously not reversible. 
6.2.2. Medicinal treatment 
In the 1960s it was discovered that medicines could be administered to patients 
suffering from Parkinson's disease that effectively treated the symptoms of the disease. 
Although not without drawbacks, medicinal treatments were hailed as a great 
improvement over ablation treatments. Medicinal treatments for Parkinson's disease 
remain common and are effective for nearly all but the most advanced cases. 
Levodopa (medicinal L-dopa) is the most popular medicine for the treatment of 
Parkinson's disease, as it is converted into dopamine (DA) by the body itself. Dopamine 
cannot easily be delivered to the body, as it is unable to cross the blood-brain barrier. L-
dopa, however, may be ingested and then cross into the brain, where it is converted into 
dopamine in the substantia nigra pars compacta. Although the substantia nigra pars 
compacta may be degraded because of cell death, the cells that do remain are able to 
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produce a quantity of dopamine from the L-dopa that mimics the amount of dopamine 
produced by a healthy substantia nigra when the medication is titrated correctly. 
Medicinal L-Dopa is not without downsides, however. Levodopa can only be 
used in the earlier stages of Parkinson’s disease and becomes less effective over time. In 
very severe, advanced cases of Parkinson's disease, enough of the substantia nigra pars 
compacta has died that L-dopa treatment is no longer effective. Without a sufficient 
number of dopamine-making cells in the substantia nigra pars compacta, not enough 
dopamine is created even with the help of extra L-dopa [Rosenzweig et al, 2005].  
Below is a list of the side-effects of the use of L-Dopa: 
 
Common side-effects 
 Abnormal thinking: holding false 
beliefs that cannot be changed by 
fact 
 Agitation 
 Anxiety 
 Clenching or grinding of teeth 
 Clumsiness or unsteadiness 
 Confusion 
 Difficulty swallowing 
 Dizziness 
 Excessive watering of mouth 
 False sense of well being 
 Feeling faint 
 General feeling of discomfort or 
illness 
 Hallucinations (seeing, hearing, or 
feeling things that are not there) 
 Hand tremor, increased 
 Nausea or vomiting 
 Numbness 
 Unusual and uncontrolled 
movements of the body, including 
the face, tongue, arms, hands, head, 
and upper body 
 Unusual tiredness or weakness 
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Not so common side-effects: 
 Blurred vision 
 Difficult urination 
 Difficulty opening mouth 
 Dilated (large) pupils 
 Dizziness or lightheadedness when 
getting up from a lying or sitting 
position 
 Double vision 
 Fast, irregular, or pounding 
heartbeat 
 Hot flashes 
 Increased blinking or spasm of 
eyelids 
 Loss of bladder control 
 Mental depression 
 Other mood or mental changes 
 Skin rash 
 Unusual weight gain or loss 
  
Rare side-effects: 
 Back or leg pain 
 Bloody or black tarry stools 
 Chills 
 Convulsions (seizures) 
 Fever 
 High blood pressure 
 Inability to move eyes 
 Loss of appetite 
 Pain, tenderness, or swelling of foot 
or leg 
 Pale skin 
 Prolonged, painful, inappropriate 
penile erection 
 Sore throat 
 Stomach pain 
 Swelling of face 
 Swelling of feet or lower legs 
 Vomiting of blood or material that 
looks like coffee grounds   
[MAYO, 2012] 
Some of the side-effects to taking the drug L-dopa are the effects encountered from 
Parkinson’s disease. 
 Monoamine oxidase inhibitors (MAOIs) are also used to treat Parkinson’s 
disease. Degradation of dopamine in the synapse by monoamine oxidase can be blocked 
by monoamine oxidase inhibitors. By preventing monoamine oxidase from breaking 
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down dopamine after it has been released into the synapse, the effects of dopamine are 
amplified. Some of the side-effects by using MAOIs are sexual dysfunction, 
sleeplessness, dizziness, gaining weight, muscle aches or tingling and difficulty 
urinating. MAOI’s also interfere with the metabolism of vitamin B6 and can cause the 
muscle ache or tingling [NBM, 2012]. 
Adenosine (A2A) antagonist is another type of medicine that has been studied, 
because levodopa does not seem to work for longer terms. A2A does not focus on  the 
dopamine receptors, but rather on the adenosine receptors. Adenosine has, like 
dopamine, an important role in the basal ganglia. The A2A receptors are mostly 
localised near the dopamine receptors in the striatum, the basal nuclei that receives the 
most projections from the substantia nigra pars compacta. Blocking the A2A receptors 
should decrease the motor complications of Parkinson’s disease [Hickey & Stacy, 
2012]. 
There are two kinds of adenosine receptors that are well researched: A1 and A2A 
adenosine receptors. A1 receptors are common throughout the brain and prevent the 
release of excitatory neurotransmitters when they are bound with adenosine. A2A 
receptors are found in very high concentration in the basal ganglia and have a very 
different effect when active. A2A receptors deactivate A1 adenosine receptors. Put 
another way, A1 receptors inhibit the release of excitatory neurotransmitters; A2A de-
inhibits, removes the inhibition caused by A1 adenosine receptors. A2A receptors are 
only activated when A1 adenosine receptors are highly active, when the neuron is 
receiving many inhibitory signals. By blocking the A2A receptors, the check on the 
amount of inhibition that adenosine can cause is removed [Cunha, 2008]. 
As discussed in section 5.3, cell death can occur from excitotoxicity. 
Excitotoxicity stemming from over-active glutamate circuits is of particular concern in 
Parkinson's disease. One potential way of mitigating this issue is to take full advantage 
of the inhibitory effects of the A1 adenosine receptors by blocking the A2A adenosine 
receptors in the basal ganglia. Blocking A2A receptors has been shown not only to 
prevent further degeneration in patients with Parkinson's disease, but also to reduce the 
motor symptoms of Parkinson's disease [Cunha, 2008]. 
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6.2.3. Stem Cell Therapy  
Replacement of dead cells in the substantia nigra pars compacta with induced 
pluripotent stem cells (iPSCs) is one of the newer, experimental treatments for 
Parkinson's disease. Treatment with induced pluripotent stem cells is focused on 
restoring the damage caused by the death of dopaminergic neurons. A number of studies 
have found that mouse embryonic cells are able to be reprogrammed in mice to these 
iPSCs. As of 2012, researchers have also succeeded in transforming human cells into 
iPSCs [Pu et al, 2012]. The major issue with this treatment is how to turn these iPSCs 
into exactly what is needed for the patient. Currently it is not possible to replicate the 
dopaminergic neurons in the substantia nigra pars compacta, because the connections 
between the neurons are too numerous. Transplanting such an amount of cells is too 
risky to attempt in vivo. 
6.2.4. Deep brain stimulation 
 Deep brain stimulation is a treatment that involves directly targeting certain 
areas of the brain with electrical impulses that are administered via surgically implanted 
electrodes. Although invasive, deep brain stimulation accompanied by pharmaceutical 
treatment, such as levodopa, is known to be better than any pharmaceutical treatment 
alone. A series of randomized control trials performed by Deuschl et al. have 
demonstrated that deep-brain stimulation is more effective than medicinal treatment 
[Deuschl et al, 2006]. Furthermore, deep brain stimulation is efficient even after 
pharmaceuticals alone can no longer effectively treat the symptoms of Parkinson’s 
disease. As such, deep brain stimulation has become a popular treatment for Parkinson’s 
disease in the later stages of the disease.  
Deep brain stimulation targets structures in the basal ganglia in order to 
counteract the motor problems that are characteristic of Parkinson’s disease. Common 
targets for deep brain stimulation for the treatment of Parkinson’s disease are the 
subthalamic nucleus (STN), the globus pallidus (GPi), the ventralis intermedius (Vim) 
thalamus. The subthalamic nucleus is the most common target, although different areas 
are targeted depending upon the specifics of the symptoms in the patient. Stimulation of 
the STN is helpful in treating all motor symptoms of Parkinson's disease. The ventralis 
intermedius thalamus is often targeted when tremor is the main issue. Deep brain 
stimulation of the GPi is effective for treating dyskinesias [Shah et al., 2010]. In the 
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case of Parkinson's disease, deep brain stimulation is typically used as a treatment for 
patients for whom pharmaceutical L-Dopa has worked in the past, but who are suffering 
from motor problems despite the medication. Typical protocols stipulate that candidates 
for deep brain stimulation should still respond to L-Dopa and should not show signs of 
dementia. If patients do the effect of deep brain stimulation will not be efficient enough 
compared to the risks of the surgery [Hickey & Stacy, 2011]. 
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7. Deep brain stimulation 
In a healthy brain, the substantia nigra produces a steady stream of dopamine 
directed at the striatum and the other basal ganglia, regardless of whether the body is 
moving or at rest [Hickey & Stacy, 2011]. Deep brain stimulation is a treatment that 
employs a surgically implanted neurostimulating device which sends electrical impulses 
to interfere with the patient's neural impulses. The deep brain stimulation device 
functions as a pacemaker which stimulates a target area of the brain. The impulses of 
the deep brain stimulation device can, for example, help control movement and block 
the abnormal neural signals that arise as a result of neural degradation in patients 
suffering from Parkinson's disease [NINDS, 2012]. 
7.1. History 
 The development of deep brain stimulation started in 1870 when Eduard Hitzig 
and Gustav Fritsch performed the first direct electrical stimulation of the motor cortex 
in dogs that could not move their limbs due to anaesthesia [Fritsch & Hitzig, 2009].  
Robert Bartholow used the same treatment in 1874, but this time  on a human subject 
[Harris & Almerigi, 2009]. Today, the deep brain stimulation system is widely used, but 
it was not until the 1990s that it was adopted by mainstream neurosurgery for the 
treatment of Parkinson's disease.  
Timeline of deep brain stimulation
 
 In 1870 Eduard Hitzig and Gustav Fritsch did an experiment on dogs' cerebrums 
in Berlin, Germany. They experimented on the frontal part of the cerebrum, because the 
motor part lies in that area. Anesthetized, the dogs could not move their limbs. By 
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electrical stimulation of the frontal part of the cerebrum in one side of the brain, Hitzig 
and Fritsch observed muscle contractions in the other side of the body. They also 
discovered that there was a correlation between current and  responding muscles, 
wherein a higher current corresponded to larger groups of muscles responding [Fritsch 
& Hitzig, 2009].  
 Robert Bartholow from Medical College of Ohio, USA worked in 1874 at Good 
Samaritan Hospital where he was presented to Mary Rafferty. Rafferty had arrived at 
the hospital with a 5 centimetre hole in her skull, which she had had for 13 months.  
 
Figure 7.1.1. shows a drawing of Mary Rafferty's head, with exposed cortex [Harris & Almerigi, 2009] 
 Rafferty gave her permission to Bratholow to study and experiment on her brain. 
This gave Bartholow the opportunity to redo and improve Hitzig and Fritsch’s 
experiment from 1870, this time with a human subject. His experiment was to stimulate 
different parts of the brain with different current strength to see the respond. The result 
were contractions of leg and arm, dilated pupils, unpleasant tingling in arm and leg, 
spasms of arm, loss of consciousness, 20 minutes in a coma and pain. After four days 
and six tests, Rafferty died of unknown causes [Harris & Almerigi, 2009]. 
 In 1954, James Olds and Peter Milner from McGill University, Canada 
performed an experiment involving deep brain stimulation, this time of the midbrain. 
Olds and Milner's experiment involved 15 male rats with electrodes surgically 
implanted in their midbrains. Each rat was placed in a skinner box, a testing chamber 
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for experiments in operant conditioning. From the top of the box, a lead connected the 
electrodes placed in the rats' brains to a voltage source. The rats would receive a 
stimulating current to the dopamine reward centre in the brain every time the rats 
activated the lever in the Skinner box. This experiment showed that electrical 
stimulation in primary reward centre increased the occurrence of the target behaviour, 
lever pressing, while stimulation of the other sites had either no effect or the opposite 
effect [Olds & Milner, 1954].  Although the dopamine pathway involved in this 
experiment is not the same as in Parkinson’s disease, Olds and Milner demonstrated that 
dopaminergic neurons can be stimulated with electrical impulses. 
 
Figure 7.1.2 Shows the Skinner box Olds and Milner used in 1954  
 In 1972 Bechtereva et al, from the Institute for Experimental Medicine in 
Leningrad, Russia performed a study on patients with parkinsonian hyperkinesia to find 
connections between different brain parts and parkinsonian symptoms by using 
electrical stimulation in caudate nucleus and globus pallidus. Because of this 
experiment they found a lack of connection between caudate nucleus and medial globus 
pallidus, where it would have existed in  a normally functional brain. Therefore they 
concluded that there had to be some kind of causal relation between parkinsonian 
hyperkinesia and the medial globus pallidus [Bechtereva et al, 1972]. 
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 In 1994, Jean Siegfried and Bodo Lippitz from the Division of Neurosurgery, 
Klinik im Park in Zurich, Switzerland published an article about a 12-year study of 
chronic electrical stimulation of the brain with a surgically implanted, programmable 
neuropacemaker. The goal of the experiment was to see a reduction of dyskinesia 
(involuntary movement) using deep brain stimulation. The study involved patients with 
a variety of illnesses: 43 patients with Parkinson’s disease, nine patients with tremor of 
multiple sclerosis, eight patients with essential cerebellar tremor, one patient with post-
traumatic tremor, six patients with post-stroke dyskinesia, and one patient with 
hemiballismus (violent and uncontrolled movement). The patients had received deep 
brain stimulation in one of the following brain areas: ventral intermediate nucleus 
(Vim), globus pallidus or the ventral pallidum. Furthermore, some of the patients had 
electrode implantation on only one side of the brain (unilateral) while other patients had 
electrode implantation on both sides of the brain (bilateral). The experiment proved a 
success and the researchers concluded that treatment using chronic electrical stimulation 
was effective and had a low to no risk of damaging the brain [Siegfried & Lippitz, 
1994]. 
 In 1997, the first approval by the United States Food & Drug Administration 
(USFDA) was given for the use of deep brain stimulation as a treatment for tremor. 
Since then, the approval has also been given to Parkinson’s disease in 2002, dystonia in 
2003, and Obsessive-Compulsive Disorder in 2009. Deep brain stimulation has been 
suggested for a range of other diseases, such as epilepsy, however approval has not yet 
been given by the USFDA [Graves, 2010]. 
7.2. Use of deep brain stimulation 
As mentioned in the previous paragraph, deep brain stimulation (DBS) is used as 
a treatment in many different diseases which can be separated into movement disorder, 
affective disorder, and non-movement disorders. Deep brain stimulation is used as a 
treatment for: 
 Chronic pain is a long lasting pain. Pain is separated into 2 different categories: 
acute pain and chronic pain. The borderline between acute and chronic pain varies 
from 30 days to 12 months depending on the scientists, but the mark is normally at 
3 or 6 months. The reason why the range changes so much is because some 
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scientists use the expression "pain that extends beyond the expected period of 
healing" to define when it is a chronic pain. 
 Parkinson’s disease is a disease where the dopamine-generating cells in the 
substantia nigra are degenerated and destroyed. Dopamine makes muscle 
movement smooth and continuous, and therefore will some of the effects of PD be 
tremor, dystonia etc.  
 Tremor is involuntary shaking of a part of the body. Tremor is separated into 
essential tremor and parkinsonian tremor.  
 Essential tremor is an inherited tremor which usually begins around the 50 
years. It normally starts in the hands and the later to other parts of the body. 
 Parkinsonian tremor is the resting tremor seen in patients with Parkinsonism. 
It is slow and regular movements, typically in the hands but also in other parts 
of the body. The tremor normally stops by a voluntary movement. 
 Dystonia is a neurological disorder givinguncontrolled muscles contractions which 
causes repeated twisting or abnormal postures. There can be several reasons for this 
condition. It can be inherited, or it can be for example be caused by lack of oxygen 
at birth, infection, poisoning or allergic reaction to pharmaceuticals. 
 Bipolar-disorder formerly known as manic-depressive disorder is a serious and 
drastic mood change from mania to depression. Patients normally experience 
changing episodes of mania and depression. 
 Spasmodic      torticollis   or cervical dystonia is a type of dystonia. Muscles 
contractions in the neck make the neck have involuntarily turns. It is caused by an 
increased transport of the neurotransmitter acetylcholine in the muscles of the neck 
and it normally predominantly idiopathic but it can also develop as a reaction to 
another disease. 
 Major depression or Major depressive disorder (MDD) is a diseasewhere the 
patient has low self-esteem and has lost joy in normal activities. In the more severe 
cases patients can have tendencies to get psychosis, delusions and hallucinations. 
Patients with major depressions can also be suicidal. 
 Obsessive-Compulsive Disorder (OCD) is an anxiety disorder where the patient 
have intrusive thoughts that create anxiety, fear or concern, and by doing a 
repetitive behaviours they reduce their anxiety. OCD can also be a combination of 
1. Semester project: Deep brain stimulation as a treatment for Parkinson’s disease 
Kevin von Heymann-Horan, Mie Primdahl Nielsen, Amir Zoet, and Tina Becher Østerbøg   Page 32 
 
obsessive and compulsive behaviour. Some of their repetitive behaviours can for 
example be excessively washing, religious thoughts, sexual thoughts, and nervous 
rituals. 
 Epilepsy is a disease where the patient has abnormal neural impulses, which can 
result in seizures. Some scientists have different definitions of epilepsy. For some it 
requires that seizures be recurring and unprovoked, and for others it requires one 
seizure and a brain alteration, this alteration increases the risk of more seizures in 
the future. 
 Tourette’s syndrome is a neuropsychiatric disorder. It is a genetic inherited 
disorder which starts during childhood. The patient has several motoric tics and as a  
minimum one vocal tic. These tics can be transient or chronic. 
[Information about the diseases have been modified form Wikipedia and 
TheFreeDictionary by Farlex] 
 Scientists have  started experimental treatments with DBS on patients with post-
traumatic coma and Lesch-Nyhan syndrome. Post-traumatic coma is a condition 
wherein the patient has been diagnosed with a persistent vegetative state due to brain 
damage. Tsubokawa et al have done experimental treatment on patients with post-
traumatic coma where the patients have received electrical stimulation in many different 
parts of the brain. The experiment showed impressive results: several patients awoke 
from the coma and started to regain simple motor skills [Tsubokawa et al, 1990]. Lesch-
Nyhan syndrome is a genetic disorder where the patient will have self-harming 
behaviour. In an experiment, Deon et al used deep brain stimulation to treat a boy with 
severe self-harming behaviour. After two and a half years with deep brain stimulation 
the boy showed almost no self-harming behaviour [Deon et al, 2012]. The results of 
Deon et al's experiment is exciting because it shows that deep brain stimulation can be 
used to treat neuropsychiatric diseases in addition to the neuromotor disorders for which 
it is currently in common use. 
7.3. Surgery 
There are different stages in deep brain stimulation procedure. First, the patient 
receives a magnetic resonance imaging (MRI) or a computed tomography (CT) scan to 
locate the target area. There are different target areas depending on which of the 
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diseases mentioned above (section 7.2) is to be treated. The target areas in deep brain 
stimulation for movement disorders are the internal globus pallidus (GPi), subthalamic 
nucleus (STN), ventral intermediate nucleus (Vim) of the thalamus [Wichmann & 
Delong, 2011] and researchers have found a new target area, the pedunculopontine 
nucleus (PPN) [Hamani et al, 2011]. The target areas in deep brain stimulation for 
affective and non-movement disorders are the hypothalamus, inferior thalamic peduncle 
(part of the thalamus), subgenual cingulate cortex (part of the cerebral cortex), anterior 
internal capsule (part of the white matter, and separates thalamus and globus pallidus) 
and GPi. 
When the target area or areas have been located the surgery can begin. First, a 
hole with a diameter of 14 mm is drilled in the skull so that the three components of the 
deep brain stimulation device can be placed. First there is the lead, a thin electrode, the 
tip of which is placed at the target area in the brain [NINDS, 2012]. Second, the 
extension, a wire, is run under the skin of the head, neck, and shoulder either to the 
collarbone or to just above the abdomen where the third component, the internal pulse 
generator (IPG), is placed [NINDS, 2012]. The extension is connected the internal pulse 
generator. The internal pulse generator sends electrical impulses through the extension, 
to the lead, and into the brain to interfere with the patient’s neural impulses.
 
Figure 7.3.1 Shows how and where the deep brain stimulation device is placed, and how the lead 
is connected to the extension and the implanted pulse generator 
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There cannot be a standard for every installation of the electrode and the exact 
placement must be tailored to each patient. Installations will be different because the 
amount of decay that the brain cells (glial cells, myelinated axons) will have 
experienced in each patient. The glial cells and myelinated axons of the neurons will 
respond differently to the electrical current from the deep brain stimulation device and, 
therefore, the precise placement will be unique for each patient. The patient is under 
local anesthesia when the lead is implanted. When the patient is under local anesthesia 
the surgeons can see right away if the lead is place correct or if it needs to be moved. 
The surgeons test the placing of the lead, by turning on the deep brain stimulation 
device; if it is placed correct there will be visible improvement of the patients 
symptoms. 
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8. Deep brain stimulation and Parkinson’s disease 
Deep brain stimulation is offered to patients with severe, advanced Parkinson's 
disease. Patients in Denmark with Parkinson’s disease can only get the deep brain 
stimulation surgery if they have severe symptoms and if they are under 70-years-old 
[Østergaard, 2012]. When treating Parkinson's disease, there are four different target 
areas: the internal globus pallidus (GPi), subthalamic nucleus (STN), ventral 
intermediate nucleus (Vim) of the thalamus and the pedunculopontine nucleus (PPN). 
The most commonly used targeted area is the subthalamic nucleus. Stimulation of the 
subthalamic nucleus and internal globus pallidus provides an improvement of 
dyskinesia, bradykinesia and akinesia, while Vim-DBS only improves dyskinesia, and 
PPN-DBS improves akinesia [Hickey & Stacy, 2011]. Typically, the improvements to 
rigidity, tremor, and brady-/akinesia are nearly immediate and complete. 
Stimulation of GPi and STN improve a wider range of symptoms but they 
improve it differently. GPi-DBS makes the medication (for example L-dopa) more 
effective. It does not work direct against the symptoms, but by making the medication 
more effective it will improve the symptoms. The reason why STN is the most 
commonly used target area is because it improves all the symptoms and it still works 
after the medication has stopped [Krause et al., 2001].  
8.1. Oscillations: possible explanation of the mechanism of DBS? 
The exact mechanisms that underlie the salutary effects of deep brain stimulation 
as a treatment for Parkinson's disease are not fully understood. It had previously been  
thought that deep brain stimulation worked by simulating ablation (see section 6.2.1),  
but the current consensus is that DBS works via a much different mechanism. The death 
of the dopaminergic cells of the substantia nigra creates the initial disruption that leads  
to the motor symptoms of Parkinson's disease. The lack of dopamine creates basal  
ganglia-wide disruptions in the firing patterns of the various basal nuclei. It is  
thought that deep brain stimulation overrides this arrhythmia or asynchrony in much 
the same way that a pacemaker does for a heart. 
The changes in the firing patterns, oscillations, in basal ganglia structures are  
currently being studied by many neuroscientists. The oscillation patterns are thought to  
be a key to understanding dysfunctional basal ganglia activity. The oscillations are  
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different when the body is at rest and when performing voluntary movement. The  
subthalamic nucleus is thought to be responsible for some of the synchronization of  
oscillations in the basal ganglia. Stimulation of the subthalamic nucleus between 130 
and 180 Hz typically provides effective treatment for Parkinson's disease. The exact 
reason why this range of frequencies is effective is unknown, though it is possible that 
the stimulation is interfering with the signals from the malfunctioning subthalamic 
nucleus in a way that stops the outputs from the subthalamic nucleus from disrupting 
the functions of other nuclei [Lozano & Mahant, 2004]. 
8.2. Side-effects of deep brain stimulation 
The side-effects of deep brain stimulation can be separated into 16 issue classes, 
which can be furthermore separated into 4 different groups. We are going to have our 
focus on the 4 main groups. Group 1 is the “Therapeutic effects” where some of the 
side-effects can be; abnormal motor effects or patients responding differently to their 
medication as levodopa. Group 2 is the “Medical and technical intervention” and some 
of the side-effects in this group can be surgery related side-effects like internal bleeding, 
damaged tissue due to lowered blood flow and infections, it can also be problems with 
the deep brain stimulation device. Group 3 is the “Affective, behavioural and cognitive 
side-effects”. These side-effects can be compulsive shopping, gambling, hyper 
sexuality, cognitive and memory decline, mood changes, depression, suicide attempts, 
decline in speech abilities and a general lowering of life- and social qualities. Group 4 is 
“Other issues”, which can be epilepsy, abnormal weight gain/loss, hallucinations, 
sleeping disorders and drooling [Christen et al, 2012]. 
8.2.1. Deep brain stimulation candidates 
 Parkinson’s disease patients are carefully selected, for a deep brain stimulation 
surgery to avoid or lower the risk of getting the side-effects mentioned in section 8.2. 
Patients who have speech problem, neck rigidity and problems walking, as levodopa 
non-responsive symptoms would not be good candidates to deep brain stimulation 
because they would not respond that well to stimulation. There are also some 
Parkinsonian symptoms which would be more effectively treated with medication than 
deep brain stimulation, like hypophonia (soft speech, because of bad coordination in the 
vocal musculature), apraxia of eyelid opening (difficulty initiating opening and closing 
the eyelids) and depressions. Some patients with a severe case of cognitive dysfunctions 
1. Semester project: Deep brain stimulation as a treatment for Parkinson’s disease 
Kevin von Heymann-Horan, Mie Primdahl Nielsen, Amir Zoet, and Tina Becher Østerbøg   Page 37 
 
(compared to the normal level in Parkinson’s patients) can worsen their cognitive 
dysfunctions if they receive the deep brain stimulation surgery [Lozano & Mahant, 
2004]. 
8.2.2. Deep brain stimulation and language/cognitive functions  
Subthalamic nucleus deep brain stimulation has been shown to alleviate some 
psychiatric disorders that are found with Parkinson's disease, namely anxiety and 
depression [Wolz et al, 2012]. Subthalamic nucleus deep brain stimulation has been 
shown to cause a decline in language abilities in experiments that compare patients to 
healthy controls and to other Parkinson's patients who are being treated with 
medications alone [Phillips et al, 2012]. Soon after treatment, STN deep brain 
stimulation is linked with worsened verbal abilities when the device is switched on, 
when compared to pre-operative conditions. This may be due, however, to a 
decrease/cessation of L-Dopa treatment and not to the effects of DBS itself [Lefaucheur 
et al, 2012]. Given how effective deep brain stimulation is in treating the motor 
symptoms that are the primary, dominant feature of Parkinson's disease, it is unlikely 
that the small effects found in the experiments by Phillips et al and Lefaucheur et al are 
likely to dissuade patients with advanced Parkinson's from considering DBS as a 
treatment for their condition. 
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9. Examination of case study and experiment 
As mentioned above several clinical studies have demonstrated the efficacy of DBS in 
PD patients. Below two more specific and special investigations of the use of DBS are 
described. We chose an experiment which focused on a specific symptom of 
Parkinson’s disease. This experiment was interesting, because it was not just about 
treating the normal symptoms like tremors, but it was also focusing on a specific 
symptom which can have a big impact on Parkinson’s patients. For the case study, we 
wanted to see the good things and the bad things of getting deep brain stimulation. Also 
the case study shows the steps of the surgery, and the follow up. Which we thought was 
interesting, because we have written so much about the deep brain stimulation surgery, 
we then wanted to have a case where it was used, and then explained. 
9.1. Close examination of experiment: Sunstedt et al, 2012 
Recent experiments have tried new approaches to using deep brain stimulation 
to treat certain side-effects of Parkinson’s disease more effectively. This experiment 
tested stimulation of the caudal zona incerta to alleviate side effects problems that 
sometimes arise from the more popular subthalamic nucleus DBS. 
9.1.1. Introduction 
Dysphagia, swallowing difficulty, is a symptom in patients with idiopathic 
Parkinson’s increasing the mortality risk due to aAspiration pneumonia, inflammation 
of the lungs caused by food or other material falling into the lungs. Dysphagia has been 
reported to be the highest source of mortality amongst the side-effects of idiopathic 
Parkinson’s. Dysphagia has been reported in some patients as a complication of STN 
DBS. In a long term follow up, 15% of patients that received STN DBS showed this 
adverse effect. [Liang G et al, 2006]. Accordingly, it is important to account for 
dysphagia as a side effect when considering treatments for Parkinson’s. 
The swallowing effect can be divided into four phases: Pre-oral, oral, pharyngeal 
and esophageal, described in detail below: 
Phase 1: Pre-Oral. 
In the pre-oral stage, the food is in the mouth where it is chewed and moisturized with 
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saliva. Here both muscles and tongue are involved, and therefore Parkinson’s disease 
can impair this function. 
Phase 2: Oral. 
The food from the mouth gets transported to the pharynx (back of the throat), where the 
soft palate elevates to avoid food going into the nose, and the back of the tongue pushes 
the food to the back of the throat. In the oral stage, the tongue and the palate at are 
important. 
Phase 3: Pharyngeal. 
The food moves into the esophagus. Breathing stops while this phase is in action, so that 
food travel to the lungs/airways is prevented.  
Phase 4: Esophageal. 
The food goes through the esophagus and gastroesophageal junction into the stomach. 
Aspiration pneumonia is mainly associated with deterioration in the pharyngeal phase. 
The most common treatment for Parkinson’s disease is the medication levodopa. This 
medication does not seem to affect the risk of Dysphagia as a side-effect. Deep brain 
stimulation (DBS) in the subthalamic nucleus (STN) is the more common therapy used 
for Parkinson’s patients, although the posterior subthalamic area including the caudal 
zona incerta (cZI) has been suggested also as a therapy for parkinson’s patients. The 
effect of STN DBS on swallowing function has been evaluated in a single study; cZI 
DBS showed to improve some aspects of the pharyngeal stage of deglutition (i.e. 
swallowing) where the oral stage was not affected. The effect of cZI DBS on 
swallowing has not been described in the literature, except for a case where the patient 
got transient dysphagia because of a misplaced electrode. Therefore it is also of great 
importance to not only evaluate the effects of caudal zona incerta DBS on the primary 
motor symptoms of Parkinson's disease (tremor, rigidity, etc.), but also to consider the 
therapies’ effects on swallowing function. 
The purpose of this study was to compare the post-operative status with regard to 
dysphagia (6 and 12 months), with a baseline made before surgery,  to see the negative 
and the positive effects of the surgery on symptoms. This swallowing analysis is part of 
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a larger randomized study, which is performed on patients who would normally be 
treated with STN DBS but instead received cZI DBS. 
9.1.2. Method 
The cZI is located adjacent to the STN, it has excitatory glutaminergic 
connections to the substantia nigra. A correct location for the electrodes was chosen 
with a CT scan fused with the MRI. That means that the location was found, by looking 
at the CT scans, and the MRI scans, so that they would find the best location. The post-
operative examinations were done with an optimized dose of levodopa. Any changes in 
the patients’ devices or medication were only done if the situation and the specialist 
called for it. 
9.1.3. Results of the experiment. 
There were no significant changes in swallowing function pre –operatively with 
or without the normal medication. Pre-operative and post-operative comparisons 
showed that there was a significant reduction of pre-swallow spillage, with and without 
stimulation. 6 months after surgery there was found no difference in the swallowing 
function. 12 months after surgery there was significantly more pre-swallow spillage 
with the stimulator on than with it off.  
This study examined the effect of cZI DBS on pharyngeal swallowing function in a 
heterogeneous group of patients with Parkinson’s disease. Sundstedt et al mention that 
they consider the number of participants acceptable, but low taking into consideration 
the amount of patients having these surgeries done [Sundstedt et al, 2012]. The main 
finding at the 1-year follow-up was that cZI DBS did not significantly increase the 
prevalence of penetration (which is a pre stage of aspiration) or aspiration, nor was there 
any increased occurrence of pharyngeal residue or decreased clearance because of the 
stimulation or the operation itself. It is very important to know, that an operation like 
cZI DBS therapy minimized the patient’s overall motor disturbances, but it does not 
significantly impair these aspects of swallowing. Preswallow spillage was the only 
swallowing parameter that was significantly affected by the surgery itself and by the 
DBS. Since it was lower after 6 months, it seemed that the surgery had improved the 
pre-swallow spillage symptoms. After 12 months, it seemed that the stimulation had a 
negative effect on the pre-swallow spillage, since there was more with stimulation than  
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without.  It is difficult to explain why the pre-swallow spillage was lower after 6 
months, but worse after 12 months. There was rather low prevalence of penetration and 
no aspirations in the studied group. Another study has shown that aspiration does not 
occur in Parkinson’s patients until around 10 years into the disease course. For patients 
in the current study, the assessment of percentage deterioration in swallowing function 
altered the subjective experience of swallowing related aspects of quality of life. With 
all the results given by the small group, the conclusion is that cZI DBS did not have a 
negative outcome on swallowing function. [Sundstedt et al, 2012]  
9.2. Close examination of a case study: Bejjani et al, 1999. 
The case report is about a 67-year-old, right-handed woman with a 30-year 
history of Parkinson’s disease. The patient suffered from severe rigidity, severe akinesia 
and moderate tremor while resting.  These symptoms persisted despite daily treatment 
with 900 mg of levodopa, 2.5 mg of pergolide, a dopamine receptor agonist, and 3 to 5 
mg of lorazepam, a benzodiazepine that can be used as an anticonvulsant and muscle 
relaxant. Furthermore, the patient suffered from disabling dyskinesias, a side-effect 
induced by levodopa. She had no history of psychiatric disorders or depression, nor had 
she had any mood fluctuations while receiving levodopa. 
The patient underwent a bilateral implantation of electrodes in the subthalamic 
nucleus. During surgery, four electrodes were connected by a cable under the scalp 
extending to a programmable pulse generator placed under the skin in the subclavicular 
area, similar to where a cardiac pacemaker would be placed. Each one of the electrodes 
had four contacts numbered from 0 to 3, over a length of 7.5 mm. By having multiple 
contacts on each, surgeons were able to place the electrode and then test each contact to 
find which stimulated the target most effectively.    
  To identify the optimal sight, the effect of stimulation through each of the 
four contacts of each electrode was evaluated 10 days after surgery, 12 hours after the 
most recent dose of levodopa. The voltage of stimulation was increased in increments of 
0,1 V, from 0 to 5 V, with a five minute plateau after every additional 0,5 V. This was 
done until a satisfactory reduction in symptoms of Parkinson’s disease was obtained or 
an adverse effect was discovered.  
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Under the postoperative evaluation, the patient’s face showed profound sadness 
within five seconds after a continuous monopolar 2.4-V rectangular current with a pulse 
width of 60 microseconds and a frequency of 130Hz was delivered for seven minutes 
through contact 0 of the electrode implanted on the left. The patient was still alert and 
awake, and yet the patient leaned to the right and started to cry. The patient showed all 
signs of a major depression. There were no hallucinations and no changes in her motor 
or cognitive symptoms of Parkinson’s disease. The depression disappeared fewer than 
90 seconds after the stimulation had stopped. The stimulation was performed at least 
twice through the other contacts of each electrode, without eliciting the psychiatric, 
depression response again. 
Stimulation through upper contacts 1 and 2 on the left electrode and contact 2 on 
the right electrode reduced motor symptoms of Parkinson’s disease on the contralateral 
side. With this success, the patient was treated with continuous bilateral stimulation 
through contact 1 and 2 of the left electrode and contact 2 of the right electrode.  Drug 
therapy was stopped one month after the surgery. The patient’s disability dropped from 
a high disability to almost no Parkinson’s disease symptoms.  
To verify the reproducibility of the depressive mode, the stimulation through 
contact 0 of the left electrode was repeated twice on two successive days, 20 and 21 
days after surgery. The stimulation was performed in the same manner as during the 
original episode, where both the left and the right electrodes had been turned off for one 
hour. On the first day of the experiment, stimulation was performed 12 hours after the 
latest dose of levodopa. On the second day, a 200 mg dose of levodopa was 
administered an hour before the study to obtain maximal improvement of motor skills. 
To control for placebo effects the patient was not aware of whether the stimulation was 
real or simulated.  
On the first day, after the bilateral stimulation was stopped the patient’s 
parkinsonian symptoms increased, but her mood remained the same. When current was 
applied through contact 0 of the left electrode the patient’s facial expression changed 
within seconds and the patient became extremely depressed, as during previous 
stimulation through the same contact. After the stimulation had ended the patient’s 
mood returned to normal within a minute. The same stimulation was done the day after 
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and again the stimulation elicited symptoms of depression, without diminishing any of 
the parkinsonian symptoms. The patient also cried more and moved her arms and head 
more than on the previous day.  
Eight months after the surgery, the patient was examined again. Two hours after 
stimulation was turned off, positron emission tomography with oxygen-15-labeled water 
(PET scan) was performed to obtain images of the patient's brain. Five images were 
recorded after five minutes of stimulation through contact 0 of the left electrode. Five 
more images were recorded eight minutes after stimulation was stopped. Stimulation 
was done in a randomized fashion, so the patient was unaware of whether the 
stimulation was real or simulated. During stimulation the patient showed both acute 
sadness, although less severe than during previous sessions, and the sensation that her 
body was being sucked into a hole. The illusion of bodily motion was not accompanied 
by hallucinations or confusion. A significant increase of blood flow in the right parietal 
lobe, in the left orbitofrontal cortex, in the left globus pallidus, and also in the left 
amygdala and anterior thalamus were detected by the PET scan. 
 
Figure 9.2.1. This picture shows the increased blood flow while stimulation is on. 
The patient’s score for dyskinesia dropped from 9 to 0 on a scale of 0 to 13, her 
motor skills score went from 5 to 0 on a scale from 0 to 7. Score  0 on the scales 
indicates that there are no disabilities. The scale is called Unified Parkinson’s Disease 
Rating Scale (UPDRS) [Bejjani et al, 1999]. 
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9.2.1 Discussion of the case 
This case is fascinating in that it shows both the ways in which deep brain 
stimulation can be effective for treating Parkinson's disease as well as demonstrating 
some of the side-effects. The woman in the study is representative of the typical patient 
who is referred to deep brain stimulation as a treatment for Parkinson's disease. 
The rapidity with which the patient's parkinsonian symptoms vanished following 
the activation of the deep brain stimulation device, after it had been properly adjusted to 
her, is illustrative of how powerful a tool DBS is for managing Parkinson's disease. She 
had been suffering from severe symptoms that persisted despite a regimen that included 
three different drugs. Additionally, one of the drugs, levodopa, was causing serious 
parkinsonian side-effects of its own. When activated, the stimulation caused the 
patient's symptoms to drop to zero. 
More interesting, perhaps, than the salutary effects are the side-effects that 
occurred when the electrodes - specifically the 0 contact of the left electrode - did not 
function as intended. Obviously, a sudden, severe depression is not what one wishes to 
inflict on a patient already suffering from Parkinson's disease. However, the fact that a 
sudden onset of depression did occur and was controllable gives many clues regarding 
the role of different brain structures in eg. mood disorders. These findings suggest that 
deep brain stimulation may be useful as a treatment for such disorders. If stimulation 
can induce a depression it may also be able to be used to reverse a depression. 
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10. Discussion: future of deep brain stimulation 
As stated in section 7.1, deep brain stimulation has existed since the 19th 
century. It was not until nearly the 21st century, however, that deep brain stimulation 
came to be used as a normal part of treatment for illnesses. Research advances in 
neurology, neurosurgery, and neuroimaging all point to the possibility that it will be in 
the 21st century that deep brain stimulation begins to reach its full potential.  
An unavoidable downside of deep brain stimulation is that implanting the device 
causes damage to brain tissue. This is a complication that does show signs of improving, 
however. Experiments by Constant et al (2012) have shown that resveratrol, a chemical 
in red wine that is thought to have salutary effects, can be used to reduce the amount of 
damage that is incurred when electrodes are placed for deep brain stimulation in rats. 
Resveratrol is a strong antioxidant. Antioxidants are important for neutralizing 
dangerous molecules in our cells. In the experiment, small tubes (cannulae) were used 
in place of electrodes in order to mimic the sort of procedure used in subthalamic 
nucleus deep-brain stimulation and to continually inject resveratrol into the rats' brains. 
The results showed greatly diminished injury (scarring, cell death, apoptosis) around the 
cannulae and a diminishment of side-effects associated with damage to the subthalamic 
nucleus, suggesting that resveratrol had a neuroprotective effect. If similar results can be 
found in resveratrol use on humans, the risk of injury from the implantation of deep-
brain stimulation devices could be greatly reduced [Constant et al, 2012].  
10.1. Should DBS be administered earlier in treatment? 
 As mentioned in section 6.2.4., deep brain stimulation is a more effective 
treatment for Parkinson's disease than any pharmaceutical treatments currently 
available. Therefore, it may be worthwhile to consider using deep brain stimulation as a 
treatment for Parkinson's disease earlier in the treatment regimen. Furthermore, deep 
brain stimulation works very well as a complement to medicinal L-Dopa treatment, 
increasing the efficacy of the drug. This is particularly true of DBS of the globus 
pallidus [Krause et al., 2001].  
 Currently, deep brain stimulation is used late in the treatment of Parkinson’s 
disease, as treatment of the disease with pharmaceuticals begins to lose effectiveness. 
Deep brain stimulation is a dramatic invasive procedure with the potential for very 
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harmful side-effects, particularly if mistakes in implantation occur during surgery. With 
that in mind, there are experiments that point to the potential ofdeep brain stimulation to 
be used as a protective measure in the brain, one that can slow the progression of 
Parkinson’s disease. Although it is not yet well understood, experiments with laboratory 
animals appear to show that cells in the substantia nigra pars compacta may become 
damaged from chemical changes resulting from an increase in subthalamic nucleus 
activity. The subthalamic nucleus is a common site for deep brain stimulation for 
Parkinson’s disease treatment and, if it is the case that increased subthalamic nucleus 
activity is killing dopaminergic cells in the substantia nigra, it may be possible to use 
deep brain stimulation to modulate, to “turn down” the activity of the STN in such a 
way as to protect the vulnerable dopamingergic cells [Hickey & Stacy, 2011]. 
 By using the argument that deep brain stimulation can provide a protective 
effect, such as the one just described, it is possible to argue that deep brain stimulation 
should be used earlier in the treatment of Parkinson’s disease. Currently, deep brain 
stimulation is a treatment that is not used until the patient's Parkinson’s disease has 
advanced severely. If deep brain stimulation can be used to protect the cells that are 
vulnerable in Parkinson’s disease, it may make sense to use deep brain stimulation 
earlier in treatment in order to slow the progress of the disease. 
 Parkinson's disease is a degenerative condition and therefore there will be 
patients whose symptoms are currently manageable with medications but, barring a 
cure, will experience a worsening over time. Given increasing longevity in the world 
today, many patients who receive a diagnosis of Parkinson's disease at a young or 
relatively young age can expect to live until their condition worsens to the point that 
treatment with DBS is necessary. They would, therefore, benefit greatly from any 
positive health effects that come from early DBS use. It is likely, also, that there will be 
those who are reluctant to undergo a costly and invasive procedure to treat a condition 
for which they are already receiving effective treatment. Although the question of how 
to lower the cost of deep brain stimulation is beyond the scope of this project, the 
following section provides information about improvements that are occurring with 
regard to deep brain stimulation and the future of DBS. 
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10.2. Closed-loop deep brain stimulation  
Local field potentials can potentially be used to regulate a closed-loop deep 
brain stimulation device. The term, local field potentials, refers to the activity of the 
neurons in a region. Action potentials, neurons firing electrical pulses to signal one 
another, occur at certain frequencies in the subthalamic nucleus. The frequency of local 
field potentials in the subthalamic nucleus for which deep brain stimulation is effective 
remains stable even after years of stimulation [Giannicola et al., 2012]. This means that 
it may be possible to develop a self-regulating deep brain stimulation device that adjusts 
itself in response to any changes in local field stimulation. By measuring local field 
potential frequency at the time of deep brain stimulation implantation, when the device 
is adjusted to have the most salutary effect and the fewest side-effects, an optimal 
frequency can be established for the patient. A self-regulating, closed-loop deep brain 
stimulation device could conceivably be developed that adjusts itself to maintain 
salutary effects using local field potentials as feedback information. 
10.3. Future of non-movement disorders 
 In 2009 was the first US Food & Drug Administration approval given to deep 
brain stimulation of a non-movement disorder. This non-movement disorder was 
Obsessive-Compulsive Disorder. Scientists have proven that deep brain stimulation in 
the nucleus accumbens is an effective and safe treatment for patients with Obsessive-
Compulsive Disorder. The nucleus accumbens is what in general talk is called dopamine 
reward centre [Denys et al, 2010]. This is an important step for deep brain stimulation 
and has opened up for broader use of deep brain stimulation in non-movement 
disorders. 
10.4. Motor cortex stimulation 
A potential alternative to deep-brain stimulation is motor cortex stimulation. 
Motor cortex stimulation is similar to deep-brain stimulation in that both procedures use 
electrodes to stimulate regions of the brain. Motor cortex stimulation, like deep brain 
stimulation, provides continuous, pacemaker-like stimulation to the areas to which it is 
applied. Motor cortex stimulation is currently used in the treatment of chronic pain, and 
it remains to be proven that motor cortex stimulation can effectively treat the symptoms 
of Parkinson's disease [Zwartjes et al., 2012]. 
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If motor cortex stimulation can be used instead of deep-brain stimulation, the 
amount of brain tissue that is damaged by the installation of the device can be reduced. 
Motor cortex stimulation, as its name implies, is used to stimulate regions of the motor 
cortex, which are superior to, and thus more accessible than, the basal ganglia. 
Furthermore, motor cortex stimulation has the potential to side-step some of the 
complications that arise from treatment with deep-brain stimulation. Motor cortex 
stimulation targets areas that are not part of the nigrostriatal dopamine pathway, which 
DBS does, and therefore treatment with motor cortex stimulation should be free of the 
dopamine-and-mood side-effects (eg depression) that sometimes occur in treatments 
that use deep-brain stimulation. 
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11. Conclusion 
 Throughout history, treatments for Parkinson's disease have been informed by 
the technology available at the time. Ablation was widespread until medicines that 
provided superior effectiveness were discovered. Deep brain stimulation - not a new 
technology when it came into use as a PD treatment in the 1990s, but one whose 
potential had not been realized - provided further improvements, allowing for treatment 
when medications  ceased to work. Deep brain stimulation allowed for a very powerful 
tool in the treatment of Parkinson's disease, but not one that was without risks. As our 
understanding of the brain becomes more sophisticated, the mechanisms by which deep 
brain stimulation works are becoming more clear, allowing it to be used more 
effectively, with fewer side effects, and with less risk of harm to the patient during 
surgery and after.  
 With this paper, we examined the literature on deep brain stimulation in order to 
answer the following questions: how does deep brain stimulation work in the treatment 
of Parkinson's disease, how effective is deep brain stimulation in treating Parkinson's 
disease, and how can deep brain stimulation be more effective? We have gathered 
information on clinical trials that show that deep brain stimulation is an effective 
treatment for Parkinson's disease, particularly for cases of severe, advanced Parkinson's. 
Review of contemporary literature on the treatment of Parkinson's disease and deep 
brain stimulation has provided evidence to show that DBS has a bright future. 
Furthermore, we have come to our own conclusions with regard to how deep brain 
stimulation can be better used, which conclusions are discussed below. 
If research showing that deep brain stimulation for Parkinson's disease provides 
a neuroprotective effect that can slow the progression of the disease, there is a powerful 
argument to be made for earlier and more regular use of deep brain stimulation in the 
therapeutic regimen for Parkinson's disease. Advanced cases of Parkinson's disease can 
render a patient debilitated and dependent on nursing care. In addition to severely 
reducing the patient's quality of life, a situation requiring constant, attentive care is 
extremely expensive and quickly overshadows the costs of DBS surgery. If deep brain 
stimulation can provide a neuroprotective effect, it can extend the effectiveness of 
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medicinal treatments, whose effects are enhanced by the use of DBS, and allow patients 
to experience substantially better quality of life at lower cost over the long run.  
It may also be possible to use deep brain stimulation on different structures of 
the basal ganglia, other than the subthalamic nucleus and globus pallidus, the most 
common locations, to increase the effectiveness of the therapy. Electrical stimulation of 
other regions of the brain, such as the motor cortex, is not strictly "deep" brain 
stimulation, but by using the same principles, more effective treatments for Parkinson's 
disease can be found. Given that deep brain stimulation is already used not only for 
Parkinson's disease, but also for epilepsy, it is likely that deep brain stimulation can also 
be used to provide help for patients with other neurological disorders, such as chronic 
depression, Tourette's syndrome, obsessive-compulsive disorder and bipolar disorder.  
These treatments should be explored vigorously. Particularly important are 
diseases such as chronic depression and bipolar disorder, which have a high risk of 
suicide. DBS will remain a valuable treatment option, not only for Parkinson's disease, 
but for other neurological disorders as well. The promise of advances in neuroimaging 
and in understanding the functional anatomy of the brain gives DBS a bright future. 
Following from our research, we recommend that deep brain stimulation be adopted in 
the earlier stages of the treatment of Parkinson's disease for most patients. We also 
conclude that much valuable knowledge can be gained by further research into the 
effects of stimulation of other regions of the brain. This research should be given a high 
priority, as it has the potential to improve lives. Research on the effectiveness of 
combinations of different drugs used in conjunction with deep brain stimulation should 
be pursued as well in order to make the most of this technology. 
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12. Wordlist 
Adenosine 
Adenosine is a neurotransmitter in the brain that interacts with dopamine in the basal 
ganglia [Hickey & Stacy, 2012]. Adenosine has an inhibitory (as opposed to excitatory) 
effect in the central nervous system [Cunha, 2008]. 
Affect 
“Affect” is a term used in psychology to describe emotion, mood, and outward, 
physical expression of emotion. 
Basal ganglia 
The basal ganglia are a collection of structures, also known as basal ganglia or basal 
nuclei, in the telencephelon and midbrain, below the cortex. The basal ganglia include 
the globus pallidus, the putamen, and the caudate nucleus. These nuclei are important 
in modulating motor functions, but do not directly stimulate movement [Rosenzweig et 
al, 2005]. The basal ganglia are among the sites commonly targeted by deep brain 
stimulation for treating Parkinson's disease. 
Cerebellum 
The cerebellum modulates motor functions and movements. The modulations of the 
cerebellum are excitatory, in contrast to the inhibitory modulations of the basal ganglia. 
Like the basal ganglia, the cerebellum helps to make movements fluid but does not 
initiate movements [McGeer et al, 1978]. 
Cerebrum 
Cerebrum is the forebrain and where the cerebral cortex and portions of the basal 
ganglia are found. The cerebrum is generally separated in front (rostral) and back 
(caudal) segments, where the front has the motor structures and the back contains the 
non-motor structures. 
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Dopamine 
Dopamine, abbreviated DA, is a monoamine, a neurotransmitter in the catecholamine 
family. Cells that synthesize dopamine are said to be ”dopaminergic.” Dopamine is 
important in learning and movement. In the brain there exist several dopamine 
pathways that regulate many aspects of behaviour [Rosenzweig et al, 2005]. 
Dopamine is synthesized from L-dopa in dopaminergic cells. Dopamine is itself a 
precursor for other monoamine neurotransmitters, such as norepinephrine and 
epinephrine [Rosenzweig et al, 2005]. 
GABA  
Gamma-Aminobutyric acid. The primary inhibitory neurotransmitter in the brain. 
Derived from glutamate. 
Globus pallidus 
The globus pallidus (GP) is a nucleus in the basal ganglia. It is, along with the 
subthalamic nucleus, one of the most popular sites for deep-brain stimulation as a 
treatment for Parkinson's disease [Follett et al, 2010]. 
Glutamate 
Glutamate is the primary excitatory neurotransmitter in the brain. An amino acid. 
Idiopathic 
An idiopathic disease is a disease where the cause of the disease is unknown or the 
disease arose spontaneously. 
L-dopa 
L-dihydroxy-phenylalanine, better known as L-dopa, is a precursor chemical in the 
synthesis of dopamine (among other neurotransmitters). L-dopa is itself synthesized 
from the amino acid, tyrosine [Widmeier et al, 2008]. 
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Lesch-Nyhan syndrome  
Lesch-Nyhan syndrome is an X-chromosome linked genetic disorder and therefore 
occurs mostly in males. It causes the lack of an enzyme “hypoxanthine guanine 
phosphoribosyltransferase” which affects the metabolism of purines and that leads to a 
high concentration of uric acid in the patient. But the hallmark of this disease is the 
patients self-harming behaviour, where they can bite off their own fingertips and lips.  
Levodopa 
Levodopa is a name for L-dopa used as a medication for the treatment of Parkinson's 
disease. 
Monoamine oxidase inhibitor 
Monoamine oxidase inhibitors (MAOIs) are a class of drug that prevent monoamine 
oxidase from breaking down dopamine (among other monoamines) for pre-synaptic 
reuptake. By so doing, MAOIs lengthen the effects of dopamine [Harsing, 2008]. 
Monoamine oxidase 
Monoamine oxidases are a class of enzymes, abbreviated as MAO. For the purposes of 
this paper, MAOs are important because they assist in breaking down dopamine for 
reuptake into the pre-synaptic neuron [Rosenzweig et al, 2005]. 
Myelinated axons 
Myelin is a substance that does not conduct electricity. It is found wrapped around 
segments of the axons of neurons. An action potential “jumps” down the axon, over the  
myelin towards the axon terminals. This is known as saltatory conduction and speeds 
intracellular communication [Gazzaniga et al, 2002]. 
Nigrostriatal pathway 
The nigrostriatal pathway is important in regulating motor functions and is one of the 
important dopamine pathways. The nigrostriatal pathway begins with the dopamine-
synthesizing neurons in the substantia nigra in the midbrain. The pathway continues to 
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the structures of the basal ganglia [Rosenzweig et al, 2005]. 
Nucleus Accumbens  
A major structure of the mesolimbic dopamine pathway. The nucleus accumbens is 
involved, notably, in reward. 
Pedunculopontine nucleus 
The pedunculopontine nucleus, abbreviated as PPN, is a structure that extends from the 
brainstem to the midbrain. It is involved in movement and is connected to the basal 
ganglia and the spinal cord. The pedunculopontine nucleus is among the structures 
commonly targeted by deep brain stimulation for the treatment of Parkinson's disease 
[Hamani et al, 2011]. 
Post-traumatic coma  
Post-traumatic coma is unconsciousness for more than six hours, where the patient 
cannot be awakened, and do not respond in any way to pain, light, sound or movement. 
Skinner box 
Skinner box is a tool in behavioural studies of operant conditioning, where the test 
subject is rewarded for doing a specific action. In Olds and Milner's experiment, rats 
had their brains' reward centres stimulated when they pressed a lever in the Skinner 
box. 
Striatum 
The striatum consists of the putamen and the caudate nucleus. The striatum is a target 
of the dopamine-producing neurons in the substantia nigra pars compacta. Outputs 
from the striatum go to the thalamus and on to the cerebral cortex [Rosenzweig et al, 
2005]. 
Substantia nigra 
The ”black substance,” abbreviated SN. The substantia nigra is a structure closely 
related to the nuclei in the basal ganglia [Rosenzweig et al, 2005]. Important to 
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Parkinson's disease is a portion of the SN called the substantia nigra pars compacta 
(SNpc). The SNpc consists of dopamine-synthesizing cells. In patients with Parkinson's 
disease, the cells of the SNpc die, resulting in an insufficient supply of dopamine 
[Widmeier et al, 2008]. 
Subthalamic nucleus 
The subthalamic nucleus is closely related to the structures of the basal ganglia. It is 
one of the preferred sites for deep-brain stimulation for the treatment of Parkinson's 
disease [Follett et al, 2010]. The subthalamic nucleus provides excitatory, 
glutaminergic input to the substantia nigra pars compacta [Chatha et al, 2000]. 
Superior 
In the brain, if Structure A is superior to Structure B, that is another way of saying that 
Structure A is “above” or “closer to the top of the organism than” Structure B. 
Synapse 
The gap between neurons where communication takes place. The neuron sending the 
message is the pre-synaptic neuron and the neuron receiving the message is the post-
synaptic neuron. 
Thalamus 
The thalamus is a structure in the diencephalon, in the forebrain, that integrates 
information from the senses, passes messages to the cerebral cortex, and helps to 
regulate attention and arousal [Widmeier et al, 2008]. The thalamus receives inputs 
from many parts of the brain; for the purposes of this paper, the thalamus is 
important as a link in the chain between the systems that are affected by Parkinson's 
disease. 
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